Launch in Europe keeps getting delayed similar to Canada. I think it's unlikely but I thought Abbott would launch earlier too.
Vitaros launches and is very unpopular. I think more people would have dropped out in the trials but you can't be sure until we see repeat sales.
Femprox has problems that haven't been discovered yet. It could happen but it a good thing the alprostadil has been out there for a while making it less likely.
Slow sales requiring more dilution. This one could happen because the company has diluted before and isn't exactly rolling in cash. My plan is to continue buying small amounts if they dilute.
Somebody could come out with a competing product that works better if we take too long. Some pharmas are very secretive and you never know when something will launch so this is always a risk.
News 
Market Data 
Discover 
AI
